"10.1371_journal.pone.0066454","plos one","2013-07-15T00:00:00Z","C Andy Schuetz; Peter Alperin; Swathi Guda; Andrew van Herick; Bertrand Cariou; David Eddy; Janusz Gumprecht; Antonio Nicolucci; Peter Schwarz; Nick J Wareham; Daniel R Witte; Ulf Smith","Archimedes, Inc., San Francisco, California, United States of America; Clinique dEndocrinologie, lInstitut du Thorax, CHU Nantes, Nantes, France; Department of Internal Diseases, Diabetology and Nephrology, Medical University of Silesia, Zabrze, Poland; Department of Clinical Pharmacology and Epidemiology, Consorzio Mario Negri Sud, Santa Maria Imbaro, Italy; Department of Medicine III Prevention and Care of Diabetes , University of Dresden, Dresden, Germany; Medical Research Council Epidemiology Unit, Institute of Metabolic Science, Addenbrookes Hospital, Cambridge, United Kingdom; Steno Diabetes Center, Gentofte, Denmark; Sahlgrenska University Hospital, Gothenburg, Sweden","Conceived and designed the experiments: CAS PA SG AvH BC DE JG AN PS NW DW US. Performed the experiments: CAS PA SG AvH BC DE JG AN PS NW DW US. Analyzed the data: CAS PA SG AvH BC DE JG AN PS NW DW US. Contributed reagents/materials/analysis tools: CAS PA SG AvH. Wrote the paper: CAS PA SG AvH BC DE JG AN PS NW DW US.","CAS, PA, SG, AvH, and DE are employees of Archimedes Inc, and declare financial support for the submitted work from Novo Nordisk Company. BC has served on the advisory panel for Novo Nordisk, and received research support from Novo Nordisk. AN has board membership for Merck Sharp & Dohme, and Novartis, does consultancy of Novo Nordisk, and has research grants from Novo Nordisk, Merck Sharp & Dohme, Eli Lilly, and Sanofi Aventis. PS is a board member of EMPERRA GmbH. The remaining authors declare no support from any organization for the submitted work. This does not alter the authors adherence to all the PLOS ONE policies on sharing data and materials.","2013","07","C Andy Schuetz","CAS",12,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA
